All In Biotech

Investigational drug · Phase 3

AG-236

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Polycythemia Vera.

Phase 3

Last checked: Nov 19, 2026Latest source record: Oct 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

1

1 still active

All registered trials

2

Any phase or sponsor naming "AG-236"

First trial start

2026

Nov 2026

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "AG-236", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Polycythemia Vera

Approved drugs for the same conditions: Hematology and blood cancers

Largest trials

Live from ClinicalTrials.gov: studies naming "AG-236" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 0 on PubMed

No PubMed records name it yet, which is common for early code-named drugs.

Also in development for Polycythemia Vera

  • BomedemstatMK-3543, IMG-7289Phase 35 trials

    Merck & Co. · Polycythemia Vera, Essential Thrombocythemia, Thrombocythemia, Essential

  • KRT-232NavtemadlinPhase 34 trials

    Kartos Therapeutics, Inc. · Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma

  • SapablursenISIS 702843, ONO-0530Phase 32 trials

    Ono Pharmaceutical Co., Ltd. · Polycythemia Vera, Phlebotomy Dependent Polycythemia Vera

  • JBI-802Phase 21 trial

    Jubilant Therapeutics Inc. · Essential Thrombocythemia (ET), Polycythemia Vera

  • SLN124Phase 21 trial

    Silence Therapeutics plc · Polycythemia Vera

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.